Compare Abbott Laboratories (ABT) vs Carlyle Group Inc (CG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Carlyle Group Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Carlyle Group Inc trades at $42.99 (market cap $15.84B). The key difference: Abbott Laboratories is far larger — about 10.5× Carlyle Group Inc's market cap, and Carlyle Group Inc pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| ABT | CG | |
|---|---|---|
Market Cap | $166.94B | $15.84B |
Sector | Health | Financials |
52-Week High | $136.62 | $69.35 |
52-Week Low | $82.57 | $40.52 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Carlyle Group (CG) trades at $44.01, up 2.76% with a P/E of 30.16 and P/S of 5.61. Recent earnings show mixed results with Q4 2025 beat but Q1 2026 miss. Technical indicators signal bearish momentum with RSI at 76.93 suggesting overbought conditions. The company maintains strong analyst support with 14 buy ratings and a $59.60 consensus price target, representing 35% upside potential from current levels.
Carlyle demonstrates solid profitability with 18.85% net margin and 9.95% ROE, though revenue declined to $3.21B in 2025. Key risks include volatile cash flow from operations and execution challenges in fundraising targets. The stock offers growth potential through strategic acquisitions like MAI Capital Management, but investors should monitor earnings consistency and private credit exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
